Nektar Therapeutics Receives a Buy from Mizuho Securities

By Jason Carr

Mizuho Securities analyst Difei Yang maintained a Buy rating on Nektar Therapeutics (NASDAQ: NKTR) today and set a price target of $103. The company’s shares closed yesterday at $93.47.

Yang commented:

“We believe Keytruda’s data reinforces our thesis on Nektar. Assuming positive data at ASCO, we believe BMS would be inclined to make a bid for Nektar given its deteriorating market position relative to Merck.”

According to, Yang is a 5-star analyst with an average return of 21.8% and a 52.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.

Currently, the analyst consensus on Nektar Therapeutics is Strong Buy and the average price target is $105.86, representing a 13.3% upside.

In a report issued on April 13, Piper Jaffray also initiated coverage with a Buy rating on the stock with a $125 price target.

Based on Nektar Therapeutics’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $95.47 million and GAAP net loss of $33.83 million. In comparison, last year the company earned revenue of $24.73 million and had a GAAP net loss of $63.87 million.

Based on the recent corporate insider activity of 82 insiders, corporate insider sentiment is negative on the stock. Last month, Christopher Kuebler, a Director at NKTR sold 40,000 shares for a total of $3,903,914.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its products contain drug candidates of therapeutic areas, including oncology, pain, anti-infectives, anti-viral, and immunology.